OmniComm’s TrialMaster EDC Selected by Sorrento Therapeutics for Cancer Research

Published on: 

Applied Clinical Trials

Sorrento Therapeutics, Inc., a clinical stage, antibody-centric, biopharmaceutical company, has signed a new agreement with OmniComm Systems, Inc., a global provider of clinical data management technology, in which they will use OmniComm’s TrialMaster EDC technology to develop clinical studies at multiple Sorrento research sites.


Read the full release here.